GoodRx announced a partnership with 60 Degrees Pharmaceuticals, effective February 2 2026, that allows eligible consumers to purchase the malaria prophylaxis drug ARAKODA® (tafenoquine) at up to 30% off the list price at more than 70,000 U.S. pharmacies nationwide.
The deal adds a high‑margin product to GoodRx’s Pharma‑Solutions segment, which grew 54% year‑over‑year to $43.4 million in Q3 2025. By expanding access to ARAKODA®, GoodRx positions itself to capture a share of the malaria‑prophylaxis market as international travel resumes, while also diversifying its revenue base beyond the traditional prescription‑discount model.
This partnership exemplifies GoodRx’s strategic shift to a B2B2C ecosystem. By creating a direct revenue‑generating channel with a manufacturer, GoodRx expands its network and data reach, reinforcing its move away from purely consumer‑discount offerings toward integrated pharma solutions.
The partnership was well received by investors in 60 Degrees Pharmaceuticals, whose shares rose 29.7% following the announcement, reflecting confidence in the expanded market access for ARAKODA®.
CEO Wendy Barnes has highlighted GoodRx’s focus on long‑term growth through increased pharma investment and direct‑to‑consumer engagement, underscoring the strategic importance of the ARAKODA® partnership as part of the company’s broader expansion plan.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.